Human leukocyte antigen class II-presented HIV-1 clade B epitopes (HLA-II HIV-1 B epitopes)

Human leukocyte antigen (HLA) class II-presented HIV-1 clade B epitopes are short peptide fragments derived from the proteins of the Human Immunodeficiency Virus type 1, specifically the B subtype, which are displayed on the surface of antigen-presenting cells (Lindestam Arlehamn et al., 2016, Cold Spring Harb Perspect Biol). These epitopes are recognized by the T-cell receptors of CD4+ T-helper cells, which are essential for coordinating the body's immune response against the virus by stimulating B-cell maturation and CD8+ T-cell recruitment (NIH/NIAID, 2023). Because clade B is the most prevalent HIV-1 subtype in the Americas, Europe, and Australia, these epitopes are central to the design of prophylactic and therapeutic vaccines (Korber et al., 2024, LANL HIV Database). Current drug development efforts, including mRNA and DNA vaccine platforms like mRNA-1644, aim to deliver these epitopes to prime the immune system to recognize and eliminate HIV-infected cells (IAVI, 2022). However, the effectiveness of targeting these epitopes is often hindered by the virus's rapid mutation rate, which allows it to escape immune detection, and the high genetic diversity of HLA molecules among different individuals (PubMed, PMID: 28253129). This target class represents a critical component of the global effort to develop an effective HIV vaccine and functional cure.

Other names

HIV-1 clade B CD4+ T-cell epitopesMHC class II-restricted HIV-1 clade B antigensHLA-DR/DQ/DP-presented HIV-1 clade B peptidesHIV-1 subtype B MHC-II epitopes

Vaccines containing these epitopes are processed by antigen-presenting cells and presented via HLA class II molecules to CD4+ T cells. This interaction triggers T-cell activation, cytokine release, and the orchestration of a broader adaptive immune response, including B-cell help and CD8+ T-cell priming, to control or prevent HIV-1 infection (Lindestam Arlehamn et al., 2016).